Robert E. George insider trades: Moleculin Biotech (MBRX) stock purchases
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Robert reports to the SEC
Open-market buys and sales
2 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Dec 26, 2023 | MBRX | ↑ Buy | 14,493 | $0.69 | $10K | Direct | Dec 27, 2023 (1d) |
| Apr 28, 2017 | MBRX | ↑ Buy | 1,000 | $0.94 | $938 | Direct | Apr 28, 2017 (0d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
About Robert E. George's insider trades
Robert E. George is a director at Moleculin Biotech (MBRX). Since Apr 28, 2017, Robert has reported 2 open-market purchases worth $11K and no sales on SEC Form 4. There have been no open-market trades in the last 12 months.
Their filings also include grants and awards (11 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every MBRX insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.